Polyclonal intravenous immunoglobulin: An important additional strategy in sepsis?

European Journal of Internal Medicine

Volumn 25, Issue 6, 2014, Pages 511-516

  Di Rosa, R ^a   Pietrosanti, M ^a   Luzi, G ^a   Salemi, S ^a   D'Amelio, R ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Immunomodulation; Intravenous immunoglobulin; Neonatal sepsis; Sepsis; Septic shock

Indexed keywords

IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SYSTEMATIC REVIEW (TOPIC); SHOCK, SEPTIC; TREATMENT OUTCOME;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; SEPSIS; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 84903386627     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2014.05.002     Document Type: Review

References (73)

1. L. Mouthon, and O. Lortholary Intravenous immunoglobulins in infectious diseases: where do we stand? Clin Microbiol Infect 9 2003 333
2. E.W. Gelfand Intravenous immune globulin in autoimmune and inflammatory diseases N Engl J Med 367 2012 2015 2025
3. S. Salemi, M. Markovic, G. Martini, and R. D'Amelio The expanding role of therapeutic antibodies Int Rev Immunol 28 2014 [Epub ahead of print]
4. M.M. Levy, A. Artigas, G.S. Phillips, A. Rhodes, R. Beale, and T. Osborn et al. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study Lancet Infect Dis 12 2012 919 924
5. D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M.R. Pinsky Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care Crit Care Med 29 2001 1303 1310
6. T. Lagu, M.B. Rothberg, M.S. Shieh, P.S. Pekow, J.S. Steingrub, and P.K. Lindenauer Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007 Crit Care Med 40 2012 754 756 [Erratum, Crit Care Med 2012;40:2932.]
7. V.Y. Dombrovskiy, A.A. Martin, J. Sunderman, and H.L. Paz Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003 Crit Care Med 35 2007 1244 1250
8. K.D. Kochanek, J. Xu, S.L. Murphy, A.M. Miniño, and K. Hsiang-Ching Deaths: preliminary data for 2009 National vital statics reports Volume 59, No 4 2011 National Center for Health Statistics Hyattsville
9. R.S. Hotchkiss, G. Monneret, and D. Payen Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach Lancet Infect Dis 13 2013 260 268
10. R.S. Hotchkiss, P.E. Swanson, B.D. Freeman, K.W. Tinsley, J.P. Cobb, and G.M. Matuschak et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction Crit Care Med 27 1999 1230 1251
11. R.S. Hotchkiss, K.W. Tinsley, P.E. Swanson, R.E. Schmieg Jr., J.J. Hui, and K.C. Chang et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4 + T lymphocytes in humans J Immunol 166 2001 6952 6963
12. R.S. Hotchkiss, K.W. Tinsley, P.E. Swanson, M.H. Grayson, D.F. Osborne, and T.H. Wagner et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis J Immunol 168 2002 2493 2500
13. M.J. Hershman, W.G. Cheadle, S.R. Wellhausen, P.F. Davidson, and H.C. Polk Jr. Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient Br J Surg 77 1990 204 207
14. C. Landelle, A. Lepape, N. Voirin, E. Tognet, F. Venet, and J. Bohe Í Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock Intensive Care Med 36 2010 1859 1866
15. X. Huang, F. Venet, Y.L. Wang, A. Lepape, Z. Yuan, and Y. Chen et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis Proc Natl Acad Sci U S A 106 2009 6303 6308
16. P. Brahmamdam, S. Inoue, J. Unsinger, K.C. Chang, J.E. McDunn, and R.S. Hotchkiss Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis J Leukoc Biol 88 2010 233 240
17. F. Venet, C.S. Chung, G. Monneret, X. Huang, B. Horner, and M. Garber et al. Regulatory T cell populations in sepsis and trauma J Leukoc Biol 83 2008 523 535
18. S. Inoue, L. Bo, J. Bian, J. Unsinger, K. Chang, and R.S. Hotchkiss Dose-dependent effect of anti-CTLA-4 on survival in sepsis Shock 36 2011 38 44
19. M.J. Delano, P.O. Scumpia, J.S. Weinstein, D. Coco, S. Nagaraj, and K.M. Kelly-Scumpia et al. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis J Exp Med 204 2007 1463 1474
20. J.A. Russell Management of Sepsis N Engl J Med 355 2006 1699 1713
21. N.C. Riedemann, R.F. Guo, and P.A. Ward The enigma of sepsis J Clin Invest 112 2003 460 467
22. G.R. Bernard, J.L. Vincent, P.F. Laterre, S.P. LaRosa, J.F. Dhainaut, and A. Lopez-Rodriguez et al. Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 2000 699 709
23. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm277212.htm. Accessed 18 Dec 2011.
24. R.P. Dellinger, M.M. Levy, A. Rhodes, D. Annane, H. Gerlach, and S.M. Opal et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012 Crit Care Med 41 2012 580 637
25. Y. Kaneko, F. Nimmerjahn, and J.V. Ravetch Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation Science 313 2006 670 673
26. C. Chen, L.H. Danekas, T.A. Ratko, P.H. Vlasses, and K.A. Matuszewski A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers Ann Pharmacother 34 2000 295 299
27. S. Sriskandan, M. Ferguson, V. Elliot, L. Faulkner, and J. Cohen Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation J Antimicrob Chemother 58 2006 117 124
28. V.S. Negi, S. Elluru, S. Sibéril, S. Graff-Dubois, L. Mouthon, and M.D. Kazatchkine et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action J Clin Immunol 27 2007 233 245
29. A. Samuelsson, T.L. Towers, and J.V. Ravetch Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor Science 291 2001 484 486
30. H. Kawasaki, K. Hayashi, and M. Awai Disseminated intravascular coagulation (DIC): immunohistochemical study of fibrin-related materials (FRMs) in renal tissues Acta Pathol Jpn 37 1987 77 84
31. M.S. Maddur, J. Vani, P. Hegde, S. Lacroix-Desmazes, S. Kaveri, and J. Bayry Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin J Allergy Clin Immunol 127 2011 823 830
32. A. Kessel, H. Ammuri, R. Peri, E.R. Pavlotzky, M. Blank, and Y. Shoenfeld et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function J Immunol 179 2007 5571 5575
33. A. Ephrem, S. Chamat, C. Miquel, S. Fisson, L. Mouthon, and G. Caligiuri et al. Expansion of CD4 + CD25 + regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis Blood 111 2008 715 722
34. J. Trinath, P. Hegde, M. Sharma, M.S. Maddur, M. Rabin, and J.M. Vallat et al. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependentprostaglandin E2 in human dendritic cells Blood 122 2013 1419 1427
35. F. Esen, E. Senturk, P.E. Ozcan, B. Ahishali, N. Arican, and N. Orhan et al. Intravenous immunoglobulins prevent the breakdown of the blood-brain barrier in experimentally induced sepsis Crit Care Med 40 2012 1214 1220
36. R. Kalaga, L. Li, J.R. O'Dell, and S. Paul Unexpected presence of polyreactive catalytic antibodies in IgG from unimmunized donors and decreased levels in rheumatoid arthritis J Immunol 155 1995 2695 2702
37. S. Planque, Y. Bangale, X.T. Song, S. Karle, H. Taguchi, and B. Poindexter et al. Ontogeny of proteolytic immunity: IgM serine proteases J Biol Chem 279 2004 14024 14032
38. J.P. Wentworth, J.E. McDunn, and A.D. Wentworth et al. Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation Science 298 2002 2195 2199
39. A. Friboulet, B. Avalle, H. Débat, and D. Thomas A possible role of catalytic antibodies in metabolism Immunol Today 20 1999 474 475
40. S. Lacroix-Desmazes, J. Bayry, S.V. Kaveri, D. Hayon-Sonsino, N. Thorenoor, and J. Charpentier et al. High levels of catalytic antibodies correlate with favorable outcome in sepsis Proc Natl Acad Sci U S A 102 2005 4109 4113
41. M.M. Alejandria, M.A. Lansang, L.F. Dans, and J.B. Mantaring Intravenous immunoglobulin for treating sepsis and septic shock Cochrane Database Syst Rev 2 2000 CD001090
42. M.M. Alejandria, M.A. Lansang, L.F. Dans, and J.B. Mantaring Intravenous immunoglobulin for treating sepsis and septic shock Cochrane Database Syst Rev 1 2002 CD001090
43. J. Pildal, and P.C. Gotzsche Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review Clin Infect Dis 39 2004 38
44. K.B. Laupland, A.W. Kirkpatrick, and A. Delaney Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis Crit Care Med 35 2007 2686 2692
45. K.G. Kreymann, G. de Heer, A. Nierhaus, and S. Kluge Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock Crit Care Med 35 2007 2677 2685
46. K. Olas, H. Butterweck, W. Teschner, H.P. Schwarz, and B.M. Reipert Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells Clin Exp Immunol 140 2005 478 490
47. A.F. Turgeon, B. Hutton, D.A. Fergusson, L. McIntyre, A.A. Tinmouth, and D.W. Cameron et al. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis Ann Intern Med 146 2007 193 203
48. A. Ohlsson, and J.B. Lacy Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants Cochrane Database Syst Rev 2 2001 CD000361
49. A. Ohlsson, and J. Lacy Intravenous immunoglobulin for suspected or subsequently proven infection in neonates Cochrane Database Syst Rev 1 2004 CD001239
50. A. Ohlsson, and J.B. Lacy Intravenous immunoglobulin for suspected or subsequently proven infection in neonates Cochrane Database Syst Rev 3 2010 CD001239
51. M.M. Alejandria, M.A. Lansang, L.F. Dans, and J.B. Mantaring III Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock Cochrane Database Syst Rev 9 2010 CD001090
52. M.M. Alejandria, M.A. Lansang, L.F. Dans, and J.B. Mantaring III Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock Cochrane Database Syst Rev 2 2013 CD001090
53. INIS Collaborative Group, P. Brocklehurst, B. Farrell, A. King, E. Juszczak, and B. Darlow et al. Treatment of neonatal sepsis with intravenous immune globulin N Engl J Med 365 2011 1201 1211
54. R.P. Dellinger, M.M. Levy, J.M. Carlet, J. Bion, M.M. Parker, and R. Jaeschke et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008 Intensive Care Med 34 2008 17 60
55. K.N. Haque, C. Remo, and H. Bahakim Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis Clin Exp Immunol 101 1995 328 333
56. H.B. Reith, and U. Mittelkotter Markers of inflammation for prognosis and therapy control in patients with abdominal sepsis - options for using adjunct intravenous immunoglobulin E. Faist, Immunological screening and immunotherapy in critically ill patients with abdominal sepsis 2001 Springer Verlag New York, NY 15 38
57. A. El-Nawawy, H. El-Kinany, M. Hamdy El-Sayed, and N. Boshra Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study ina pediatric intensive care unit J Trop Pediatr 51 2005 271 278
58. K. Haque, M. Zaidi, and H. Bahakim IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis Am J Dis Child 142 1988 1293 1296
59. A. Norrby-Teglund, N. Ihendyane, and J. Darenberg Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections Scand J Infect Dis 35 2003 683 689
60. E. Lappin, and A.J. Ferguson Gram-positive toxic shock syndromes Lancet Infect Dis 9 2009 281 290
61. J.D. Fraser, and T. Proft The bacterial superantigen and superantigen-like proteins Immunol Rev 225 2008 226 243
62. H. Basma, A. Norrby-Teglund, Y. Guedez, A. McGeer, D.E. Low, and O. El-Ahmedy et al. Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity Infect Immun 67 1999 1871 1877
63. A. Norrby-Teglund, R. Kaul, D.E. Low, A. McGeer, D.W. Newton, and J. Andersson et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production J Immunol 156 1996 3057 3064
64. J. Darenberg, N. Ihendyane, J. Sjölin, E. Aufwerber, S. Haidl, and P. Follin et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo controlled trial Clin Infect Dis 37 2003 333
65. A. Norrby-Teglund, N. Ihendyane, R. Kansal, H. Basma, M. Kotb, and J. Andersson et al. Relative neutralizing activity in polyspecific IgM, IgA, and IgG preparations against group A streptococcal superantigens Clin Infect Dis 31 2000 1175 1182
66. A. Norrby-Teglund, K.N. Haque, and L. Hammarström Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis J Intern Med 260 2006 509 516
67. H.G. Kress, C. Scheidwig, H. Schmidt, and R. Silber Reduced incidence of postoperative infection after intravenous administration of an immunoglobulin A and immunoglobulin M-enriched preparation in anergic patients undergoing cardiac surgery Crit Care Med 27 1999 1281 1287
68. S. Buda, A. Riefolo, R. Biscione, E. Goretti, I. Cattabriga, and G. Grillone et al. Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery J Cardiothorac Vasc Anesth 19 2005 440 445
69. M. Hentrich, K. Fehnle, H. Ostermann, J. Kienast, Cornely, and C. Salat IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial Crit Care Med 34 2006 1319 1325
70. F.S. Taccone, P. Stordeur, D. De Backer, J. Creteur, and J.L. Vincent Gamma-globulin levels in patients with community acquired septic shock Shock 32 2009 379 385
71. P.M. Myrianthefs, E. Boutzouka, and G.J. Baltopoulos Gamma-globulin levels in patients with community-acquired septic shock Shock 33 2010 556 557
72. F. Venet, R. Gebeille, J. Bancel, C. Guignant, F. Poitevin-Later, and C. Malcus et al. Assessment of plasmatic immunoglobulin G, A and M levels in septic shock patients Int Immunopharmacol 11 2011 2086 2090
73. G. Berlot, M.C. Vassallo, N. Busetto, M. Bianchi, F. Zornada, and I. Rosato et al. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis J Crit Care 27 2012 167 171